SELLAS Life Sciences Group, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 10.155 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.05B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK’s WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Details
| Name | SELLAS Life Sciences Group, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 13 |
| Founded | 2012 |
| Ceo | Angelos Stergiou |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US81642T2096 |
| Cusip | 81642T209 |
| Cik | 1390478 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, Chief Executive Officer and Director |
| John Thomas Burns CPA | Senior Vice President and Chief Financial Officer |
| Dr. Dragan Cicic M.D., MBA | Senior Vice President and Chief Development Officer |
| Stacy E. Yeung | Vice President, General Counsel and Corporate Secretary |
| Andrew Elnatan | Senior Vice President of Regulatory Affairs, CMC and Quality |
Contact
| Address | 7 Times Square, Suite 2503, New York, New York 10036, United States |
| Phone | 646 200 5278 |
| Website | https://sellaslifesciences.com |